On June 24, Illumina completed the divestiture of Grail, which will now operate independently and list its shares on the Nasdaq Stock Exchange under the ticker $GRAL. Grail, a cancer diagnostic test maker, aims to launch a multi-cancer blood test but faces numerous challenges as it debuts on Nasdaq. Despite high hopes for its flagship cancer test, Grail's shares fell by as much as 11.7% in their market debut. The company is betting on commercial partnerships with health systems, employers, and life sciences companies to drive its success. This marks the 'Final Resolution' of a decade of drama surrounding the acquisition.